9 December 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
Site Initiation Visit
Completed
Hemogenyx Pharmaceuticals
Successfully Completes the Site Initiation Visit of the First
Clinical Site for Phase I Clinical Trial of
HG-CT-1
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the biopharmaceutical company developing innovative
therapies for blood diseases, is pleased to announce the successful
completion of the Site Initiation Visit at the first clinical site
for its Phase I clinical trial of HG-CT-1
(also known as HEMO-CAR-T). The Phase I clinical trial is designed
as a dose escalation study to assess the safety of HG-CT-1 in adult
patients with relapsed/refractory (R/R) acute myeloid leukaemia
(AML).
Patient recruitment will begin once
the clinical site provides final details to the Company's
clinical trials manager, Prevail Infoworks.
Dr
Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals,
commented:
"This step marks a
significant milestone for the Company as we advance our lead
asset, HG-CT-1, into clinical trials. This study represents our
commitment to developing innovative therapies for patients with R/R
AML, a condition with limited treatment options.
We
are excited to see patient recruitment set to begin and take the
next steps in assessing the safety and treatment potential of
HEMO-CAR-T. We remain dedicated to delivering transformative
therapies that address critical unmet medical
needs."
About AML and CAR-T Therapy
AML, the most common type of acute
leukemia in adults, has poor survival rates (a five-year survival
rate of less than 30% in adults) and is currently treated using
chemotherapy, rather than the potentially more benign and effective
forms of therapy being developed by Hemogenyx Pharmaceuticals. The
successful development of a new therapy for AML would have a major
impact on treatment and survival rates for the disease.
CAR-T therapy is a treatment in
which a patient's own T-cells, a type of immune cell, are modified
to recognize and kill the patient's cancer cells. The procedure
involves: isolating T-cells from the patient; modifying the
isolated T-cells in a laboratory using a CAR gene construct (which
allows the cells to recognize the patient's cancer); amplifying
(growing to large numbers) the newly modified cells; and
re-introducing the cells back into the patient.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in
this announcement would have been inside information for the
purposes of Article 7 of Regulation No 596/2014 (as it forms part
of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person
responsible for arranging for the release of this announcement on
behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler,
Chief Executive Officer & Co-Founder.
Enquiries:
|
Hemogenyx
Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief Executive Officer
& Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP Angel
Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre, Adam
Cowl
|
|
|
|
|
|
Peterhouse
Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as a platform technology
that it uses as an engine for novel product development.